Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 59, Issue 19, Pages 9150-9172Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01071
Keywords
-
Categories
Funding
- Korea Technology R&D Project, Ministry of Health & Welfare, Republic of Korea [HI11C0918]
Ask authors/readers for more resources
We developed a compound library for orally available gonadotropin-releasing hormone (GnRH) receptor antagonists that were based on a uracil scaffold. On the basis of in vitro activity and CYP inhibition profile, we selected 18a (SKI2496) for further in vivo studies. Compound 18a exhibited more selective antagonistic activity toward the human GnRH receptors over the GnRHRs in monkeys and rats, and this compound also showed inhibitory effects on GnRH-mediated signaling pathways. Pharmacokinetic and pharmacodynamic evaluations of 18a revealed improved bioavailability and superior gonadotropic suppression activity compared with Elagolix, the most clinically advanced compound. Considering that 18a exhibited highly potent and selective antagonistic activity toward the hGnRHRs along with favorable pharmacokinetic profiles, we believe that 18a may represent a promising candidate for an orally available hormonal therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available